Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment

Abstract

Patients with follicular lymphoma (FL) who experience early therapy failure (ETF) within 2 years of frontline immunochemotherapy have poor overall survival (OS).We analyzed the Grupo Español de Linfomas y Trasplantes de Médula Ósea registry to determine whether autologous stem cell transplantation (ASCT) is effective in this

Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)

“…The optimal treatment approaches for patients with POD24 is not well established. The role of autologous stem cell transplantation (ASCT) has not been specifically addressed in this setting, but it represents a strategy that can induce prolonged remission in FL 10 and is commonly used in patients with early relapse after immunochemotherapy. Whether patients with early POD after immunotherapy alone would require ASCT consolidation continues to be unknown.…”

How I treat early-relapsing follicular lymphoma

“…Patients underwent transplantation after rescue treatment in CR2 or second partial response, and those in CR1 underwent ASCT for early therapy failure (lack of partial response to frontline therapy). 35 In collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) and the NLCS, we evaluated whether ASCT improves outcomes in early-relapsing FL in the rituximab era. Patients in the CIBMTR registry experienced POD24 or failure of front-line therapy and underwent ASCT for consolidation.…”

Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade

“…Retrospective data show that patients with early treatment failure after frontline therapy may also benefit from autologous SCT. [83][84][85] The patterns of recurrence following failure of auto-SCT also suggest that high-dose therapy does not compromise outcome in patient in whom this treatment fails, with median survival following relapse ranging from 5 to 8 years. 86,87 Autologous SCT in transformed FL achieves sustained remission in a high proportion of patients.…”

“…Mature follow‐up data demonstrate a plateau on the remission duration curve at 48% at 12 years, suggesting that a proportion of patients are cured with this treatment approach. Retrospective data show that patients with early treatment failure after frontline therapy may also benefit from autologous SCT . The patterns of recurrence following failure of auto‐SCT also suggest that high‐dose therapy does not compromise outcome in patient in whom this treatment fails, with median survival following relapse ranging from 5 to 8 years .…”